Key takeaways
Atogepant (Qulipta) and erenumab (Aimovig) are both medications used to prevent migraines in adults, and they belong to the class of calcitonin gene-related peptide (CGRP) receptor blockers. However, they differ in several ways. Atogepant is taken orally once a day, while erenumab is administered as an injection under the skin once a month. Both medications are available only as brand-name products, with no generic versions currently available. Common side effects of atogepant include nausea, constipation, and sleepiness, whereas erenumab may cause pain at the injection site, constipation, and high blood pressure. Additionally, atogepant can interact with many medications, such as rifampin (Rifadin) and clarithromycin. It's important to discuss with a healthcare professional which medication might be best for you based on your needs and medical history.
